☏ +1 650 501 5505 ✉ [email protected]
Methodology Contact

DI-HC-10740 Edition 1 Updated 196 pages, PDF and Excel

Asia Pacific Pharmaceutical Drug Market

Asia Pacific pharmaceutical drugs are worth USD 436.80 billion in 2025 and USD 878.84 billion by 2035 as China reimburses more innovative drugs.

By the . Next review Apr 2027. Editorial standards

Market size, 2025
$436.8B
Forecast, 2035
$878.8B
Revenue CAGR, 2026–2035
7.24%
Branded innovative small molecules share
37.4%

By product

Branded innovative small molecules, Generics and branded generics, Innovative biologics, Biosimilars, Over-the-counter (OTC) medicines

By therapy area

Oncology, Cardiovascular and metabolic, Anti-infectives, Central nervous system, Immunology, Respiratory

By channel

Hospital pharmacy, Retail pharmacy, Online pharmacy

By region

China, Japan, India, South Korea, Australia, ASEAN, Rest of Asia Pacific

See what you are buying

Get the free sample

19 chapters 45 tables 9 figures 7 company profiles 196 pages

  1. Executive summaryThe market in one view
  2. Scope and definitionsPrescription and OTC medicines in Asia Pacific
  3. Research methodologyBottom-up: billion standard units × value per unit
  4. Product segmentsInnovative, generic, biologic, biosimilar and OTC
  5. Demand driversFive forces behind 2.83% volume
  6. RestraintsJapan, hospital payment caps and stewardship
  7. PricingPrice per standard unit
  8. CountriesChina to the rest of Asia Pacific

See all chapters and sections (11 more chapters)

Key findings

  • The Asia Pacific pharmaceutical drug market is worth USD 436.80 billion in 2025 and USD 878.84 billion in 2035, a 7.24% revenue CAGR.
  • Volume adds 2.83% a year and price 4.29%, mostly from mix as units move from VBP generics to innovative biologics.
  • Branded innovative small molecules lead with 37.4%, while biosimilars grow fastest at 14.86% a year.
  • China holds USD 208.60 billion, 47.76% of value; India grows fastest at 10.64% a year and Japan slowest at 1.12%.
  • The top three sellers hold only 3.16%, led by AstraZeneca in China at about 1.52%.
MeasureValueHow it is built
Market size, 2025 $436.8B 1,872.6 billion standard units x USD 0.23326 per unit = $436.8B.
Forecast, 2035 $878.8B Base case: 2.83% volume and 4.29% price a year.
Revenue CAGR, 2026–2035 7.24%2.83% volume + 4.29% price (1.0283 x 1.0429) minus 1.
Volume, 2035 2,475.4 Bn standard units Chinese chronic disease, Indian access and ASEAN coverage, net of Japanese decline.
Leading segment Branded innovative small molecules, 37.4% $163.4B in 2025.
Fastest segment Biosimilars, 14.86% $11.8B to $47.1B.
Fastest region India, 10.64% $26.9B to $73.9B.
Market leader AstraZeneca (China), about 1.52% $6.65B 2025 China revenue over regional value; Douglas Insights estimate.
Event China's 2025 NRDL adds 114 drugs, 7 December 2025 NHSA catalogue notice, Guangzhou municipal government.

Every figure passes the desk's release checks before publication: segments add to the total, growth rates match their start and end values, and each cited source says what the report attributes to it. How the research is done

Market data

Request a free sample

A sample built around your question: the scope, structure and method of the report, with every table and chart layout from the report and Excel model. The Research Desk reviews it and emails it to you, usually within one business day.

China’s National Healthcare Security Administration (NHSA) released its 2025 national reimbursement drug list (NRDL) on 7 December 2025, adding 114 medicines, 50 of them Class 1 innovative drugs, and launching a first commercial health insurance list of 19 innovative drugs, both effective 1 January 2026, according to the Guangzhou municipal government notice. The Asia Pacific pharmaceutical drug market covers finished prescription and over-the-counter (OTC) medicines sold in China, Japan, India, South Korea, Australia, the Association of Southeast Asian Nations (ASEAN) and the rest of the region, valued at manufacturer selling prices. Douglas Insights sizes the Asia Pacific pharmaceutical drug market at USD 436.80 billion in 2025, from 1,872.6 billion standard units at an average USD 0.233 per unit, and at USD 878.84 billion in 2035, a revenue CAGR (compound annual growth rate) of 7.24%. Our regional study sits beside the global Pharmaceutical Drug Market report inside our pharmaceuticals coverage, and every figure follows the Douglas Insights research methodology.

Which companies supply the Asia Pacific pharmaceutical drug market, from AstraZeneca China to Jiangsu Hengrui?

No company holds even 2% of the Asia Pacific pharmaceutical drug market: Douglas Insights puts the top three, AstraZeneca in China, Jiangsu Hengrui and Daiichi Sankyo in Japan, at 3.16% of 2025 value. Positions rest on Chinese hospital access, Japanese oncology portfolios and Indian branded generics.

Company Asia Pacific sales disclosed What the position is built on Estimated share 2025
AstraZeneca (China) USD 6.65 billion China revenue, 2025 Oncology and respiratory medicines in Chinese hospitals 1.52%
Jiangsu Hengrui RMB 28.24 billion of drug sales, 2025 Innovative oncology drugs listed on the NRDL 0.90%
Daiichi Sankyo JPY 485.8 billion Japan Business Unit, FY2025 Antibody-drug conjugates and Japanese primary care brands 0.74%
Chugai JPY 472.4 billion domestic sales, 2025 Roche-licensed antibodies and Hemlibra 0.72%
Sun Pharma INR 192,904 million India formulations, FY26 Branded generics, 8.4% of the Indian market 0.51%
Astellas JPY 289.0 billion Japan sales, FY2025 Urology and oncology brands 0.44%

AstraZeneca and Jiangsu Hengrui in China

AstraZeneca is the largest single seller of medicines in the region. Its full-year 2025 results of 10 February 2026 show China revenue of USD 6.65 billion, up 4%, inside total revenue of USD 58.74 billion. Douglas Insights estimates that equals 1.52% of the 2025 Asia Pacific pharmaceutical drug market.

Jiangsu Hengrui is the domestic champion that the 7 December 2025 NRDL update favours most. Its 2025 annual report on the Hong Kong exchange shows revenue of RMB (renminbi) 31.63 billion, up 13.0%, with innovative drug sales of RMB 16.34 billion, up 26.1% and 58.3% of drug sales. Excluding RMB 3.39 billion of licensing income, Douglas Insights values Hengrui drug sales at USD 3.93 billion.

Daiichi Sankyo, Chugai, Astellas and Takeda in Japan

Japan’s leaders are export-led. Daiichi Sankyo reported FY2025 revenue of JPY 2,123.0 billion, up 12.6%, with its Japan Business Unit at JPY 485.8 billion, up only 1.9%, in its results of 11 May 2026. Chugai booked JPY 1,257.9 billion of 2025 revenue and JPY 472.4 billion of domestic sales, and flagged National Health Insurance (NHI) price revisions and biosimilar entry against Avastin, in its 29 January 2026 release. Astellas reported FY2025 revenue of JPY 2,139.2 billion with Japan sales of JPY 289.0 billion, up 8.2%, in its 27 April 2026 results. Takeda posted FY2025 revenue of JPY 4,505.7 billion, down 1.7%, in its 13 May 2026 release, a group total that Douglas Insights does not split by country.

Sun Pharma, BeOne, Celltrion and Samsung Biologics

Sun Pharma ranks first in India, with FY26 India formulation sales of INR 192,904 million, up 14%, and an 8.4% share on the Pharmarack moving annual total (MAT) to March 2026, in its 22 May 2026 release. BeOne Medicines, formerly BeiGene, reported 2025 revenue of about USD 5.3 billion, up 40.2%, including USD 3.9 billion from the Bruton’s tyrosine kinase (BTK) inhibitor Brukinsa, in its 2025 Form 10-K. Korea’s Celltrion reported record 2025 revenue of KRW 4.16 trillion, up 17%, in its 5 February 2026 release, and Samsung Biologics booked KRW 4.56 trillion, up 30.3%, as a contract development and manufacturing organization (CDMO), per its 21 January 2026 results. Both sell mostly abroad.

Which Asia Pacific pharmaceutical drug segment leads: branded innovative medicines, generics, biologics or OTC?

Branded innovative small molecules lead the Asia Pacific pharmaceutical drug market with 37.4% of 2025 value, worth USD 163.36 billion, while biosimilars grow fastest at 14.86% a year. Generics move 71.6% of units but earn only 31.8% of value.

Segment Share 2025 Value 2025 Growth 2026-2035 Value 2035
Branded innovative small molecules 37.4% USD 163.36 billion 6.62% USD 310.13 billion
Generics and branded generics 31.8% USD 138.90 billion 4.93% USD 224.75 billion
Innovative biologics 16.9% USD 73.82 billion 10.37% USD 198.01 billion
Over-the-counter (OTC) medicines 11.2% USD 48.92 billion 7.28% USD 98.81 billion
Biosimilars 2.7% USD 11.79 billion 14.86% USD 47.13 billion

Branded innovative small molecules earn USD 163.36 billion because Japan pays patented prices for most of its USD 79.30 billion market and China’s NRDL now reimburses targeted oral oncology drugs. Generics and branded generics hold USD 138.90 billion; Indian branded generics keep prices above Chinese volume-based procurement (VBP) tenders, which explains a value share far below their unit share.

Innovative biologics are worth USD 73.82 billion and grow 10.37% a year to USD 198.01 billion, as antibodies and antibody-drug conjugates (ADCs) from Daiichi Sankyo, Chugai and Hengrui move into reimbursement. OTC medicines add USD 48.92 billion, mostly analgesics and cold remedies sold in Japanese, Chinese and ASEAN pharmacies. Biosimilars are the smallest slice at USD 11.79 billion but rise to USD 47.13 billion; Celltrion and Samsung Bioepis supply the antibody copies. Japan’s Ministry of Health, Labour and Welfare (MHLW) estimates that biosimilars saved JPY 119.9 billion a year, inside JPY 1.24 trillion of savings from generic substitution, in its fiscal 2026 price revision summary.

Why is demand for Asia Pacific pharmaceutical drugs rising 2.83% a year in units?

Asia Pacific pharmaceutical drug volume grows 2.83% a year to 2035, from 1,872.6 billion to 2,475.4 billion standard units, and five forces explain all of it. Chinese chronic disease adds the most, 1.08 points; Indian access adds 0.71 points.

Chinese ageing and chronic disease: 1.08 points

China supplies 1.08 points of the 2.83-point volume leg. Hypertension, diabetes and dyslipidaemia patients take daily tablets for decades, and VBP tenders have cut the cost of those tablets so far that hospitals dispense more of them. The 11th VBP round announced on 15 July 2025 covered 55 generic molecules, fixed contracted volumes at 60% to 80% of hospital demand and dropped the lowest-bid price anchor, according to the Chinese government portal. Douglas Insights estimates China dispensed 902.4 billion standard units in 2025.

Indian access and Jan Aushadhi: 0.71 points

India adds 0.71 points. The Department of Pharmaceuticals counts 17,990 Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) generic medicine stores open on 31 December 2025, against a target of 25,000 by 31 March 2027, in its Annual Report 2025-26. The same report puts industry turnover growth at 13.07% in FY2024-25.

ASEAN universal coverage: 0.49 points

ASEAN adds 0.49 points. Indonesia, the Philippines and Vietnam are widening public insurance, so prescriptions for diabetes, hypertension and tuberculosis shift from untreated to treated. Douglas Insights estimates ASEAN dispensed 244.7 billion units in 2025.

NRDL listings and biologics: 0.55 points

China’s NRDL update adds 0.33 points. The 2025 list carries 3,253 drugs after 114 additions and 29 removals, effective 1 January 2026, per the Guangzhou government notice; Douglas Insights assumes a negotiated listing triples a new drug’s hospital volume within two years. Biologics, including glucagon-like peptide-1 (GLP-1) drugs for diabetes and obesity and insulin pens, add the final 0.22 points.

The five contributions, 1.08 + 0.71 + 0.49 + 0.33 + 0.22, sum to the 2.83% volume leg. Price adds 4.29% a year, mostly mix: each unit that moves from a VBP generic at USD 0.104 to an innovative biologic at USD 12.72 lifts the regional average. Douglas Insights calculates that mix adds 5.47 points to price, while Japanese NHI cuts remove 0.41, Chinese VBP 0.62 and Indian price ceilings 0.15.

What holds back Asia Pacific pharmaceutical drug volumes in Japan and Chinese hospitals?

Three restraints remove 0.64 points from Asia Pacific pharmaceutical drug volume growth, which would otherwise run at 3.47% a year. Japan’s shrinking population, Chinese hospital payment caps and antibiotic stewardship each subtract a measured slice.

Japan removes 0.29 points: the region’s second-largest pharmaceutical drug market, at USD 79.30 billion, has a falling population, so Douglas Insights holds Japanese units close to flat through 2035.

Chinese hospital payment caps remove 0.21 points. Diagnosis-related group (DRG) and diagnosis-intervention packet (DIP) payment gives hospitals a fixed fee per case, so they trim drugs per admission. Antibiotic stewardship removes 0.14 points, as China, India and Australia cut broad-spectrum anti-infective prescribing.

Where in Asia Pacific is pharmaceutical drug spending growing fastest: China, India or ASEAN?

China is the largest Asia Pacific pharmaceutical drug country at USD 208.60 billion, 47.76% of 2025 value, while India grows fastest at 10.64% a year. ASEAN is the wildcard, adding USD 59.05 billion by 2035 as public insurance widens.

Country or sub-region Value 2025 Share 2025 CAGR 2026-2035 Value 2035
China USD 208.60 billion 47.76% 8.43% USD 468.61 billion
Japan USD 79.30 billion 18.15% 1.12% USD 88.64 billion
ASEAN USD 43.60 billion 9.98% 8.94% USD 102.65 billion
Rest of Asia Pacific USD 35.90 billion 8.22% 7.79% USD 76.00 billion
India USD 26.90 billion 6.16% 10.64% USD 73.94 billion
South Korea USD 22.70 billion 5.20% 5.38% USD 38.34 billion
Australia USD 19.80 billion 4.53% 4.47% USD 30.66 billion

China grows 8.43% a year to USD 468.61 billion, because NRDL listings pull innovative drugs into hospitals faster than VBP cuts generic prices. Japan grows only 1.12% a year to USD 88.64 billion; the MHLW cut drug prices by 4.02% on a drug-spending basis from 1 April 2026.

India more than doubles from USD 26.90 billion to USD 73.94 billion at 10.64% a year, the fastest pace, from a low per-person spend and the 13.07% turnover growth the Department of Pharmaceuticals recorded for FY2024-25. ASEAN grows 8.94% to USD 102.65 billion. South Korea reaches USD 38.34 billion at 5.38%, and Australia USD 30.66 billion at 4.47%. The rest of Asia Pacific, led by Taiwan, Pakistan, Bangladesh and New Zealand, grows 7.79% to USD 76.00 billion.

In the data table the row labelled Global holds the Asia Pacific total, USD 436.80 billion in 2025, not world medicine sales; the world view sits in the Pharmaceutical Drug Market study.

How much does a unit of Asia Pacific pharmaceutical drug cost, from a VBP generic to a biologic dose?

An Asia Pacific pharmaceutical drug unit averages USD 0.233 in 2025, inside a band from about USD 0.01 for a Chinese VBP tablet to more than USD 2,000 for an oncology antibody vial. Molecule age and reimbursement status set the price, not the country alone.

Segment Units 2025 Average per unit Realised price band Basis
Generics and branded generics 1,340.8 billion USD 0.104 USD 0.01 to USD 0.30 Douglas Insights estimate
OTC medicines 428.8 billion USD 0.114 USD 0.04 to USD 0.40 Douglas Insights estimate
Branded innovative small molecules 95.5 billion USD 1.71 USD 0.50 to USD 60 Douglas Insights estimate
Biosimilars 1.7 billion USD 7.00 USD 3 to USD 250 Douglas Insights estimate
Innovative biologics 5.8 billion USD 12.72 USD 5 to USD 2,500 Douglas Insights estimate

Biologic averages look low because insulin pens and biosimilar insulins sold under Chinese tenders make up most biologic units. Australia gives a realised benchmark: the average dispensed price per Pharmaceutical Benefits Scheme (PBS) prescription rose from AUD 85.10 to AUD 91.62 in 2024-25, per the PBS Expenditure and Prescriptions Report. Douglas Insights projects the regional average unit price to rise 4.29% a year, to USD 0.355 by 2035.

Which therapy areas and channels carry Asia Pacific pharmaceutical drug sales?

Cardiovascular and metabolic medicines carry 22.1% of 2025 Asia Pacific pharmaceutical drug value, about USD 96.53 billion, and oncology 19.4%, about USD 84.74 billion. Hospital pharmacies sell 57.6% of value, because Chinese hospitals still dispense most prescriptions.

Therapy area Share of 2025 value Value 2025
Cardiovascular and metabolic 22.1% USD 96.53 billion
Oncology 19.4% USD 84.74 billion
Anti-infectives 12.6% USD 55.04 billion
Central nervous system 10.3% USD 44.99 billion
Immunology 7.2% USD 31.45 billion
Respiratory 5.3% USD 23.15 billion

The six areas hold 76.9% of value; gastrointestinal, ophthalmic and haematology products such as CSL’s plasma medicines make up the rest. CSL reported FY26 revenue of USD 15.80 billion and a net loss of USD 2.58 billion, citing a fall in the market value of albumin in China, in its 18 August 2026 results.

By channel, hospital pharmacy holds 57.6%, or USD 251.60 billion, retail pharmacy 35.1%, or USD 153.32 billion, and online pharmacy 7.3%, or USD 31.89 billion, on Douglas Insights estimates.

Which rules set Asia Pacific pharmaceutical drug prices in Japan, China, India and Australia?

Four policy tracks set Asia Pacific pharmaceutical drug prices: Japan’s NHI price revision, cut 4.02% on a drug-spending basis from 1 April 2026, China’s NRDL and VBP, India’s Production Linked Incentive (PLI) scheme and Australia’s PBS.

Japan’s MHLW notified the fiscal 2026 revision on 5 March 2026, a cut of 0.86% of medical expenses and 4.02% of drug spending, effective 1 April 2026, per its revision summary. The same document records generics at 88.8% of volume and 68.7% of value in the 2025 price survey. A year earlier, the off-year revision for fiscal 2025, starting April 2025, covered about 9,320 of 17,440 items, 53%, and cut JPY 246.6 billion from the budget, per the MHLW notice of 20 December 2024.

China’s NHSA sets reimbursed prices through NRDL negotiation and sets generic prices through VBP tenders. The commercial health insurance innovative drug list of 19 drugs from 18 companies, effective 1 January 2026 under the 2025 notice, opens a second payer for high-priced therapies.

India’s PLI scheme for pharmaceuticals carries an outlay of INR 15,000 crore from FY2020-21 to FY2028-29, with 55 selected applicants and cumulative sales of INR 3,16,797 crore by September 2025, above the INR 2,94,000 crore target, per the Department of Pharmaceuticals. Australia’s PBS listed 949 medicines across 5,164 brands at 30 June 2025, and government paid AUD 19.1 billion, 91.7% of medicine cost, per the 2024-25 PBS report.

What if China’s NRDL listings speed up or stall: where does the Asia Pacific pharmaceutical drug forecast land in 2035?

The Asia Pacific pharmaceutical drug market ends 2035 between USD 726.02 billion and USD 1.04 trillion across our three cases, around a base of USD 878.84 billion. Chinese reimbursement of innovative drugs sets most of the spread.

Case Volume leg Price leg 2035 value
Slower 1.94% 3.21% USD 726.02 billion
Base case 2.83% 4.29% USD 878.84 billion
Faster 3.58% 5.27% USD 1.04 trillion

In the slower case, VBP extends to biologics, Japan keeps cutting prices every April and the commercial list launched on 1 January 2026 stays small. In the faster case, the 7 December 2025 NRDL and commercial list, which admitted 88% of candidate drugs against 76% a year earlier, keeps widening, and India’s PLI makers win domestic share. One extra point of yearly volume growth adds USD 89.30 billion to the 2035 value; one point less removes USD 81.82 billion.

Published forecasts for Asia Pacific medicines run from about 6.3% to 7.2% a year. Our 7.24% sits at the top edge, because we price units at manufacturer selling prices and let the shift to innovative biologics carry the price leg.

Douglas Exclusive: the Asia Pacific Drug Price Reset Calendar

The Asia Pacific Drug Price Reset Calendar is a Douglas Insights model built from 6 sourced inputs: four government notices from Japan and China, the Indian Department of Pharmaceuticals annual report and one CSL filing. The calendar dates each pricing or reimbursement reset and tags its direction.

Date Reset Effect on value
20 December 2024 MHLW agrees fiscal 2025 off-year revision, JPY 246.6 billion Down, Japan
April 2025 Fiscal 2025 revision applies to 9,320 items Down, Japan
15 July 2025 11th VBP round sets rules for 55 generics Down per unit, up in volume, China
September 2025 PLI sales reach INR 3,16,797 crore Up, India
7 December 2025 NRDL adds 114 drugs; commercial list of 19 Up, China
31 December 2025 17,990 Jan Aushadhi stores open Up in volume, India
1 January 2026 NRDL and commercial list take effect Up, China
5 March 2026 MHLW notifies fiscal 2026 cut of 4.02% Down, Japan
1 April 2026 Fiscal 2026 NHI prices apply Down, Japan
18 August 2026 CSL cites albumin value fall in China Down, China plasma

Four of the ten resets cut Japanese prices, while four lift Chinese and Indian access. The finding: Douglas Insights counts about USD 4.83 billion of annual value removed by the two Japanese revisions, JPY 246.6 billion in fiscal 2025 plus 4.02% of our USD 79.30 billion Japan base in fiscal 2026, against USD 17.59 billion of value China adds in 2026 alone. A launch team choosing where to file first in Asia now gains more from an NRDL listing than from a Japanese premium price.

How does the methodology turn 1,872.6 billion units into USD 436.80 billion of Asia Pacific pharmaceutical drugs?

How this report is built

  • Every figure carries a confidence grade in the fact sheet above, and the working model ships with every licence.
  • Seven regional models sum to the global figure, with country tables in the Excel model.
  • The next scheduled review of this study is April 2027.
  • Licence holders receive it as a maintained tab in the Excel model.

Our methodology multiplies 1,872.6 billion standard units of 2025 Asia Pacific pharmaceutical drug consumption by an average USD 0.233 per unit to reach USD 436.80 billion. Units come from seven country and sub-region builds; price comes from five segment bands weighted by units.

The model covers 7 country and sub-region rows spanning 24 countries and uses 86 data points, 27 of them sourced and 59 modelled. Arithmetic: 1,872.6 billion x USD 0.23326 = USD 436.80 billion; 436,800 x (1.0283 x 1.0429)^10 = 878,836, or USD 878.84 billion. Units reach 2,475.4 billion in 2035. Currency conversions use 2025 averages of JPY 150, CNY 7.19, INR 87, KRW 1,420 and USD 0.645 per AUD.

Two cross-checks agree. First, Australian PBS spending of AUD 19.1 billion by government and AUD 1.7 billion by patients, about USD 13.42 billion, equals 67.8% of our USD 19.80 billion Australia value, leaving hospital, private and OTC sales for the rest, per the PBS report. Second, Indian turnover of INR 4,71,898 crore less exports of INR 2,45,962 crore leaves about INR 2,25,936 crore, or USD 25.97 billion, 96.5% of our USD 26.90 billion India value, per the Department of Pharmaceuticals.

Sources

  1. Guangzhou Municipal People's Government 2025 national medical insurance and commercial health insurance innovative drug catalogues (2025)
  2. Central People's Government of China 11th batch of national organised drug procurement (2025)
  3. Ministry of Health, Labour and Welfare Fiscal 2026 drug price revision summary (2026)
  4. Ministry of Health, Labour and Welfare Fiscal 2025 drug price revision (2024)
  5. Australian Government Department of Health PBS Expenditure and Prescriptions Report 2024-25 (2025)
  6. Department of Pharmaceuticals, Government of India Annual Report 2025-26 (2026)
  7. AstraZeneca Full year and Q4 2025 results (2026)
  8. Jiangsu Hengrui Pharmaceuticals 2025 annual report (2026)
  9. Sun Pharmaceutical Industries Q4 FY26 financial results (2026)
  10. CSL FY26 full year results (2026)

Which medicines count in the Asia Pacific pharmaceutical drug market, and what is excluded?

The Asia Pacific pharmaceutical drug market counts finished prescription and OTC medicines consumed in the region, valued at manufacturer selling prices after statutory discounts. Vaccines, active pharmaceutical ingredients (APIs) sold for export, dietary supplements, medical devices and pharmacy margins stay out.

Indian exports, INR 2,45,962 crore in FY2024-25, count in the buying country. Contract manufacturing revenue stays out; our Biologics Outsourcing Market study sizes it, and the Therapeutic Monoclonal Antibodies Market report follows antibody medicines worldwide. The by-therapy split covers oncology, cardiovascular and metabolic, anti-infectives, central nervous system, immunology and respiratory medicines, and the channel split covers hospital pharmacy, retail pharmacy and online pharmacy.

Inside the 196-page report

19 chapters 176 sections 45 tables, 9 figures 7 company profiles 196 pages Every table ships in the Excel model
01Executive summary12 sections

The market in one view

  1. 1.1Market snapshot, 2025 and 2035
    1. 1.1.1Market size, 2025
    2. 1.1.2Forecast, 2035
    3. 1.1.3Growth rate, 2026–2035
  2. 1.2Growth decomposition
    1. 1.2.1Volume growth (billion standard units)
    2. 1.2.2Value per unit growth
  3. 1.3Key findings
  4. 1.4Segment highlights
  5. 1.5Regional highlights
  6. 1.6Competitive highlights
  7. 1.7Douglas Insights verdict
02Scope and definitions17 sections

Prescription and OTC medicines in Asia Pacific

  1. 2.1Market definition
  2. 2.2Inclusions and exclusions
    1. 2.2.1Product types
    2. 2.2.2Therapy areas
    3. 2.2.3Exclusions
  3. 2.3Segmentation
    1. 2.3.1By product
    2. 2.3.2By therapy area
    3. 2.3.3By channel
    4. 2.3.4By region
  4. 2.4Years considered
    1. 2.4.1Base year 2025
    2. 2.4.2Forecast 2026–2035
  5. 2.5Currency and units
    1. 2.5.1Value in USD million
    2. 2.5.2Volume in billion standard units
  6. 2.6Who this report is for
03Research methodology16 sections

Bottom-up: billion standard units × value per unit

  1. 3.1Bottom-up market model
    1. 3.1.1Volume base, 2025 (billion standard units)
    2. 3.1.2Value per unit
    3. 3.1.3Forecast legs to 2035
  2. 3.2Top-down cross-checks
  3. 3.3Data triangulation
  4. 3.4Sources
    1. 3.4.1Regulators and statistics offices
    2. 3.4.2Company filings and results
    3. 3.4.3Trade and industry bodies
    4. 3.4.410 primary sources cited
  5. 3.5Confidence grading
  6. 3.6Assumptions and limitations
    1. 3.6.1Inputs
    2. 3.6.2Arithmetic
    3. 3.6.3Cross-checks
04Product segments3 sections

Innovative, generic, biologic, biosimilar and OTC

  1. 4.1Shares
  2. 4.2Growth
  3. 4.3Unit splits
05Demand drivers3 sections

Five forces behind 2.83% volume

  1. 5.1China chronic disease
  2. 5.2India access
  3. 5.3ASEAN coverage
06Restraints3 sections

Japan, hospital payment caps and stewardship

  1. 6.1Japan
  2. 6.2DRG and DIP
  3. 6.3Anti-infectives
07Pricing3 sections

Price per standard unit

  1. 7.1VBP generics
  2. 7.2Biologics
  3. 7.3PBS benchmark
08Countries3 sections

China to the rest of Asia Pacific

  1. 8.1China
  2. 8.2Japan
  3. 8.3India and ASEAN
09Regulation and pricing policy3 sections

NHI revisions, NRDL, VBP, PLI and PBS

  1. 9.1Japan
  2. 9.2China
  3. 9.3India and Australia
10Biosimilars and biologics3 sections

Antibody copies and contract supply

  1. 10.1Celltrion
  2. 10.2Samsung Biologics
  3. 10.3Japanese substitution
11Market size and forecast, 2025–20355 sections

Global value, volume and value per unit

  1. 11.1Market value, 2025–2035
  2. 11.2Volume (billion standard units), 2025–2035
  3. 11.3Value per unit, 2025–2035
  4. 11.4Year-on-year growth
  5. 11.5Growth decomposition
12Asia Pacific Pharmaceutical Drug market, by product16 sections

5 segments, value 2025–2035

  1. 12.1Overview and share, 2025 and 2035
  2. 12.2Branded innovative small molecules
    1. 12.2.1Market size and forecast, 2025–2035
    2. 12.2.2Growth outlook
  3. 12.3Generics and branded generics
    1. 12.3.1Market size and forecast, 2025–2035
    2. 12.3.2Growth outlook
  4. 12.4Innovative biologics
    1. 12.4.1Market size and forecast, 2025–2035
    2. 12.4.2Growth outlook
  5. 12.5Over-the-counter (OTC) medicines
    1. 12.5.1Market size and forecast, 2025–2035
    2. 12.5.2Growth outlook
  6. 12.6Biosimilars
    1. 12.6.1Market size and forecast, 2025–2035
    2. 12.6.2Growth outlook
13Asia Pacific Pharmaceutical Drug market, by therapy area19 sections

6 segments, value 2025–2035

  1. 13.1Overview and share, 2025 and 2035
  2. 13.2Oncology
    1. 13.2.1Market size and forecast, 2025–2035
    2. 13.2.2Growth outlook
  3. 13.3Cardiovascular and metabolic
    1. 13.3.1Market size and forecast, 2025–2035
    2. 13.3.2Growth outlook
  4. 13.4Anti-infectives
    1. 13.4.1Market size and forecast, 2025–2035
    2. 13.4.2Growth outlook
  5. 13.5Central nervous system
    1. 13.5.1Market size and forecast, 2025–2035
    2. 13.5.2Growth outlook
  6. 13.6Immunology
    1. 13.6.1Market size and forecast, 2025–2035
    2. 13.6.2Growth outlook
  7. 13.7Respiratory
    1. 13.7.1Market size and forecast, 2025–2035
    2. 13.7.2Growth outlook
14Asia Pacific Pharmaceutical Drug market, by channel10 sections

3 segments, value 2025–2035

  1. 14.1Overview and share, 2025 and 2035
  2. 14.2Hospital pharmacy
    1. 14.2.1Market size and forecast, 2025–2035
    2. 14.2.2Growth outlook
  3. 14.3Retail pharmacy
    1. 14.3.1Market size and forecast, 2025–2035
    2. 14.3.2Growth outlook
  4. 14.4Online pharmacy
    1. 14.4.1Market size and forecast, 2025–2035
    2. 14.4.2Growth outlook
15Regional analysis36 sections

7 regions

  1. 15.1Regional overview and share, 2025 and 2035
  2. 15.2China
    1. 15.2.1Market size and forecast, 2025–2035
    2. 15.2.2By product
    3. 15.2.3By therapy area
    4. 15.2.4By channel
  3. 15.3Japan
    1. 15.3.1Market size and forecast, 2025–2035
    2. 15.3.2By product
    3. 15.3.3By therapy area
    4. 15.3.4By channel
  4. 15.4India
    1. 15.4.1Market size and forecast, 2025–2035
    2. 15.4.2By product
    3. 15.4.3By therapy area
    4. 15.4.4By channel
  5. 15.5South Korea
    1. 15.5.1Market size and forecast, 2025–2035
    2. 15.5.2By product
    3. 15.5.3By therapy area
    4. 15.5.4By channel
  6. 15.6Australia
    1. 15.6.1Market size and forecast, 2025–2035
    2. 15.6.2By product
    3. 15.6.3By therapy area
    4. 15.6.4By channel
  7. 15.7ASEAN
    1. 15.7.1Market size and forecast, 2025–2035
    2. 15.7.2By product
    3. 15.7.3By therapy area
    4. 15.7.4By channel
  8. 15.8Rest of Asia Pacific
    1. 15.8.1Market size and forecast, 2025–2035
    2. 15.8.2By product
    3. 15.8.3By therapy area
    4. 15.8.4By channel
16Competitive landscape11 sections

7 companies profiled

  1. 16.1Market concentration
  2. 16.2Market share analysis, 2025
  3. 16.3Strategic moves: acquisitions, launches, contracts
  4. 16.4Company profilesEach profile: overview, products, financials where reported, position in this market, recent developments
    1. 16.4.1Korea
    2. 16.4.2AstraZeneca
    3. 16.4.3Jiangsu Hengrui
    4. 16.4.4Daiichi Sankyo
    5. 16.4.5Chugai
    6. 16.4.6Sun Pharma
    7. 16.4.7Astellas
17Scenarios to 20355 sections

Slower, base and faster

  1. 17.1Slower case
  2. 17.2Base case case
  3. 17.3Faster case
  4. 17.4Sensitivity of the 2035 value
  5. 17.5Published forecasts compared
18Douglas Exclusive: the Asia Pacific Drug Price Reset Calendar3 sections

Ten dated price and reimbursement resets

  1. 18.1Calendar
  2. 18.2Japan versus China
  3. 18.3Finding
19Appendix5 sections

Data, sources and licence

  1. 19.1Data tables (Excel model)
  2. 19.2Sources (10)
  3. 19.3Abbreviations
  4. 19.4Change log and next review
  5. 19.5Licence and how to cite
TList of tables45
  1. Table 1Market value, 2025–2035 (USD million)
  2. Table 2Volume, 2025–2035 (billion standard units)
  3. Table 3Value per unit, 2025–2035
  4. Table 4Asia Pacific Pharmaceutical Drug market by product, 2025–2035 (USD million)
  5. Table 5Branded innovative small molecules: market size, 2025–2035 (USD million)
  6. Table 6Generics and branded generics: market size, 2025–2035 (USD million)
  7. Table 7Innovative biologics: market size, 2025–2035 (USD million)
  8. Table 8Over-the-counter (OTC) medicines: market size, 2025–2035 (USD million)
  9. Table 9Biosimilars: market size, 2025–2035 (USD million)
  10. Table 10Asia Pacific Pharmaceutical Drug market by therapy area, 2025–2035 (USD million)
  11. Table 11Oncology: market size, 2025–2035 (USD million)
  12. Table 12Cardiovascular and metabolic: market size, 2025–2035 (USD million)
  13. Table 13Anti-infectives: market size, 2025–2035 (USD million)
  14. Table 14Central nervous system: market size, 2025–2035 (USD million)
  15. Table 15Immunology: market size, 2025–2035 (USD million)
  16. Table 16Respiratory: market size, 2025–2035 (USD million)
  17. Table 17Asia Pacific Pharmaceutical Drug market by channel, 2025–2035 (USD million)
  18. Table 18Hospital pharmacy: market size, 2025–2035 (USD million)
  19. Table 19Retail pharmacy: market size, 2025–2035 (USD million)
  20. Table 20Online pharmacy: market size, 2025–2035 (USD million)
  21. Table 21Asia Pacific Pharmaceutical Drug market by region, 2025–2035 (USD million)
  22. Table 22China: market by product, 2025–2035 (USD million)
  23. Table 23China: market by therapy area, 2025–2035 (USD million)
  24. Table 24China: market by channel, 2025–2035 (USD million)
  25. Table 25Japan: market by product, 2025–2035 (USD million)
  26. Table 26Japan: market by therapy area, 2025–2035 (USD million)
  27. Table 27Japan: market by channel, 2025–2035 (USD million)
  28. Table 28India: market by product, 2025–2035 (USD million)
  29. Table 29India: market by therapy area, 2025–2035 (USD million)
  30. Table 30India: market by channel, 2025–2035 (USD million)
  31. Table 31South Korea: market by product, 2025–2035 (USD million)
  32. Table 32South Korea: market by therapy area, 2025–2035 (USD million)
  33. Table 33South Korea: market by channel, 2025–2035 (USD million)
  34. Table 34Australia: market by product, 2025–2035 (USD million)
  35. Table 35Australia: market by therapy area, 2025–2035 (USD million)
  36. Table 36Australia: market by channel, 2025–2035 (USD million)
  37. Table 37ASEAN: market by product, 2025–2035 (USD million)
  38. Table 38ASEAN: market by therapy area, 2025–2035 (USD million)
  39. Table 39ASEAN: market by channel, 2025–2035 (USD million)
  40. Table 40Rest of Asia Pacific: market by product, 2025–2035 (USD million)
  41. Table 41Rest of Asia Pacific: market by therapy area, 2025–2035 (USD million)
  42. Table 42Rest of Asia Pacific: market by channel, 2025–2035 (USD million)
  43. Table 43Company market shares, 2025
  44. Table 44Scenario values, 2035
  45. Table 45Sources and confidence grades by figure
FList of figures9
  1. Figure 1Market value, 2025–2035
  2. Figure 2Growth decomposition, 2026–2035
  3. Figure 3Share by product, 2025 and 2035
  4. Figure 4Share by therapy area, 2025 and 2035
  5. Figure 5Share by channel, 2025 and 2035
  6. Figure 6Share by region, 2025 and 2035
  7. Figure 7Growth by region, 2026–2035
  8. Figure 8Market concentration, 2025
  9. Figure 9Scenario paths to 2035

Email me the sample and full contents Buy the report

Questions buyers ask

What is the Asia Pacific pharmaceutical drug market worth in 2025 and 2035?

USD 436.80 billion in 2025, from 1,872.6 billion standard units at USD 0.233 each, rising to USD 878.84 billion by 2035 at a 7.24% revenue CAGR.

What did China's 2025 national reimbursement drug list change?

114 drugs were added, 50 of them Class 1 innovative drugs, and a separate commercial health insurance list of 19 innovative drugs was launched, both effective 1 January 2026.

How hard did Japan cut drug prices in April 2026?

4.02% on a drug-spending basis, effective 1 April 2026, after a fiscal 2025 revision that cut JPY 246.6 billion; Japan grows only 1.12% a year to 2035 in our model.

Which Asia Pacific pharmaceutical drug segment earns the most?

37.4% of 2025 value, or USD 163.36 billion, sits in branded innovative small molecules, while generics move 71.6% of units but earn 31.8% of value.

Which Asia Pacific country grows fastest in pharmaceutical drug spending?

10.64% a year for India, from USD 26.90 billion to USD 73.94 billion, on low spending per person and the 13.07% turnover growth recorded for FY2024-25.

How concentrated are Asia Pacific pharmaceutical drug sellers?

3.16% of 2025 value sits with the top three, AstraZeneca in China, Jiangsu Hengrui and Daiichi Sankyo in Japan, so no company holds even 2% of the market.

Which Asia Pacific pharmaceutical drug type grows fastest?

14.86% a year for biosimilars, from USD 11.79 billion to USD 47.13 billion, as Celltrion and Samsung Bioepis antibody copies replace originals.

How far apart are the slower and faster 2035 cases?

USD 726.02 billion in the slower case and USD 1.04 trillion in the faster case, against a USD 878.84 billion base, set mainly by Chinese reimbursement of innovative drugs.

Part of the global studyPharmaceutical Drug Market (global) →
Related data Drug pipeline reviews by therapy area

Research & citation

This report was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Cite this report Douglas Insights Inc (2026). Asia Pacific Pharmaceutical Drug Market. Report DI-HC-10740, October 2026. https://www.douglasinsights.com/asia-pacific-pharmaceutical-drug-market/

Data for this market

Drug pipeline reviews by therapy areaDrug pipeline. Every drug candidate in clinical development for a therapy area, counted by phase from registered trials and reviewed by the research desk, with sponsors, readouts and a 40–50 page review.